

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: March 30, 2016	
Re.: Press Release.	


Dear Sir / Madam,

We enclose herewith a copy of press release dated March 30, 2016 under the title “Zydus’ Neshor Pharmaceuticals, receives its first ANDA approval for Dextroamphetamine IR Tabs which will be manufactured at the Neshor Plant, USA”. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus' Neshor Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs

The drug will be manufactured at the Neshor Plant, USA

Ahmedabad, 30 March 2016

Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received its first ANDA approval from the USFDA to market Dextroamphetamine IR Tabs. The drug falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Neshor. The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sales for Dextroamphetamine IR Tabs is \$40.6 mn as per IMS.

Neshor has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances, which otherwise cannot be imported.
